Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$20.04
-2.7%
$28.92
$19.16
$48.25
$975.72M1.27698,141 shs639,230 shs
CONMED Corporation stock logo
CNMD
CONMED
$34.79
+1.1%
$36.47
$32.13
$56.63
$1.05B0.92467,205 shs381,190 shs
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
$11.29
-6.9%
$0.00
$10.87
$18.79
$285.30MN/A93,790 shs58,391 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$16.60
+5.1%
$17.75
$9.98
$29.65
$1.14B1.582.70 million shs1.93 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
0.00%-0.49%-12.57%-44.91%-30.92%
CONMED Corporation stock logo
CNMD
CONMED
0.00%-0.78%-4.36%-6.72%-38.98%
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
0.00%-25.92%+1,128,999,900.00%+1,128,999,900.00%+1,128,999,900.00%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.00%-14.17%+17.31%-23.11%-22.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$20.04
-2.7%
$28.92
$19.16
$48.25
$975.72M1.27698,141 shs639,230 shs
CONMED Corporation stock logo
CNMD
CONMED
$34.79
+1.1%
$36.47
$32.13
$56.63
$1.05B0.92467,205 shs381,190 shs
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
$11.29
-6.9%
$0.00
$10.87
$18.79
$285.30MN/A93,790 shs58,391 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$16.60
+5.1%
$17.75
$9.98
$29.65
$1.14B1.582.70 million shs1.93 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
0.00%-0.49%-12.57%-44.91%-30.92%
CONMED Corporation stock logo
CNMD
CONMED
0.00%-0.78%-4.36%-6.72%-38.98%
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
0.00%-25.92%+1,128,999,900.00%+1,128,999,900.00%+1,128,999,900.00%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.00%-14.17%+17.31%-23.11%-22.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
2.75
Moderate Buy$46.17130.38% Upside
CONMED Corporation stock logo
CNMD
CONMED
1.86
Reduce$39.5013.53% Upside
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
0.00
N/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.48
Hold$29.8479.77% Upside

Current Analyst Ratings Breakdown

Latest CNXU, TNDM, CNMD, and AORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
DowngradeSell (D-)Sell (E+)
6/10/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
DowngradeStrong-BuyHold
6/8/2026
Artivion, Inc. stock logo
AORT
Artivion
DowngradeHold (C-)Sell (D+)
6/4/2026
CONMED Corporation stock logo
CNMD
CONMED
Reiterated RatingSell (D)
6/1/2026
Artivion, Inc. stock logo
AORT
Artivion
Set Price Target$45.00
6/1/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
UpgradeBuyOverweight$21.00 ➝ $27.00
5/28/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Reiterated RatingNeutral$22.00 ➝ $17.00
5/27/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Set Price Target$21.00
5/26/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
UpgradeSell (E+)Sell (D-)
5/20/2026
Artivion, Inc. stock logo
AORT
Artivion
Reiterated RatingHold (C-)
5/18/2026
CONMED Corporation stock logo
CNMD
CONMED
Lower Price TargetNeutral$52.00 ➝ $40.00
(Data available from 6/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$441.33M2.20$1.10 per share18.24$9.46 per share2.12
CONMED Corporation stock logo
CNMD
CONMED
$1.37B0.76$7.20 per share4.83$33.36 per share1.04
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
N/AN/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$1.01B1.12N/AN/A$2.29 per share7.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
$9.77M$0.2483.5026.72N/A2.55%7.15%3.63%8/6/2026 (Estimated)
CONMED Corporation stock logo
CNMD
CONMED
$47.06M$1.7719.667.201.714.00%13.84%6.05%7/29/2026 (Estimated)
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$204.71M-$1.40N/A415.00N/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)

Latest CNXU, TNDM, CNMD, and AORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million
4/29/2026Q1 2026
CONMED Corporation stock logo
CNMD
CONMED
$0.82$0.89+$0.07$0.45$310.64 million$317.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
CONMED Corporation stock logo
CNMD
CONMED
N/AN/A-5.59%N/AN/A
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.48
3.86
2.80
CONMED Corporation stock logo
CNMD
CONMED
0.85
2.29
1.04
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
N/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.54
3.58
3.07

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
CONMED Corporation stock logo
CNMD
CONMED
N/A
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
N/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
6.30%
CONMED Corporation stock logo
CNMD
CONMED
0.28%
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
N/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,80048.54 million45.49 millionOptionable
CONMED Corporation stock logo
CNMD
CONMED
3,90030.11 million30.03 millionOptionable
Conexeu Sciences Inc. stock logo
CNXU
Conexeu Sciences
425.27 millionN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,50068.53 million67.09 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Artivion stock logo

Artivion NYSE:AORT

$20.04 -0.56 (-2.72%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$20.11 +0.07 (+0.35%)
As of 06/12/2026 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

CONMED stock logo

CONMED NYSE:CNMD

$34.79 +0.38 (+1.11%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$34.78 -0.02 (-0.05%)
As of 06/12/2026 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Conexeu Sciences stock logo

Conexeu Sciences NASDAQ:CNXU

$11.29 -0.84 (-6.92%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$12.24 +0.96 (+8.46%)
As of 06/12/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$16.60 +0.80 (+5.06%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$16.60 +0.00 (+0.03%)
As of 06/12/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.